Search results
Found 31107 matches for
NDORMS professors serve on NIHR Urgent Public Health Group
11 June 2020
Sion Glyn-Jones and Matt Costa are members of the Covid 19 Urgent Public Health Group coordinating trials to address health impacts of the pandemic.
Oxford leads part of major COVID-19 drugs trial
10 June 2020
NDORMS Professor Duncan Richards and Dr Matt Rowland (Nuffield Department of Clinical Neurosciences) are leading the Oxford arm of a new UK trial to investigate whether administering the anti-inflammatory drug infliximab to patients with COVID-19 can prevent progression to respiratory failure or death.
Could do better: clinical trial reporting fails to live up to the mark
8 June 2020
The statistical analysis and reporting of treatment effects in reports of randomised trials with a binary primary endpoint requires substantial improvement, suggests NDORMS research published in BMC Medicine.
First patient recruit for key drug treatment trial
5 June 2020
A clinical trial to test whether Azithromycin, a commonly used antibiotic, can treat the symptoms of COVID-19 in outpatients has recruited its first patient.
New atlas of stromal cells maps out potential for treating human fibrosis
4 June 2020
Research at the Kennedy Institute reveals sub-populations of stromal cells with distinct functions in human fibrotic disease. These findings could inform development of more specific therapies with fewer off-target effects.
Understanding of inflammatory bowel disease moves a step closer
23 May 2020
Published in Science Immunology, researchers at the Kennedy Institute have identified the role of IRF5 in controlling intestinal inflammation.
Dr. Michael Dustin joins Strategic Research Collaboration with Cue Biopharma
14 May 2020
The research will test innovative technology that harnesses the body’s intrinsic immune system to transform the treatment of cancer and autoimmune diseases.
New weapon identified in arsenal against disease
11 May 2020
Researchers in the Dustin Group reveal supramolecular attack particles are autonomous killing entities released from cytotoxic T lymphocytes
Managing clinical trials during the pandemic
4 May 2020
Duncan Richards, Climax Professor of Clinical Therapeutics and Director of the Oxford Clinical Trials Research Unit (OCTRU) is interviewed about clinical trials and the challenges of running them in a pandemic.
The NDORMS response to COVID-19
30 April 2020
A number of members of the department are actively helping with the response to the COVID pandemic. Playing a key role in research, literature reviews, clinical trials and engineering projects, all have a shared commitment to collaborate globally to tackle the pandemic.
Professor Fiona Powrie elected to the National Academy of Sciences in the USA
29 April 2020
Fiona was recognised for her outstanding contributions to immunology, and her election brings the number of current National Academy of Sciences members from the Kennedy Institute to three.
Live imaging shows surprising passage of T cells in the spleen
16 April 2020
Research from Tal Arnon’s group at the Kennedy Institute reveals a network of perivascular pathways that guide T cells into the spleen.
Childhood obesity increases the risk of fracture new study finds
9 April 2020
Overweight or obese pre-school children have a higher risk of bone fractures during childhood than those of normal weight according to a new study published in the Journal of Bone & Mineral Research.
COVID-19 prognosis and prediction models for medical decision-making are flawed, say researchers
7 April 2020
The modelling and approach to tackle the hard medical decisions associated with the spread of the COVID-19 virus may be based on weak and overly-optimistic evidence from studies that are biased and unreliable, suggests research published by The BMJ today.
Professor Alan Silman receives Nuffield Foundation grant for research into joint replacement surgery
7 April 2020
The three year funding will provide evidence on how musculoskeletal conditions progress and their effect on people’s well-being and life chances.
Oxford-led research describes the safety profile and potential harms of hydroxychloroquine and azithromycin
2 April 2020
Over 300 international researchers from the Observational Health Data Sciences and Informatics (OHDSI) community studied data from almost 1 million patients. They declared hydroxychloroquine safe for short-term use, but urge caution in using it in combination with azithromycin.